The α-camera: A quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of α-particles

Journal of Nuclear Medicine

Volumn 51, Issue 10, 2010, Pages 1616-1623

  Bäck, Tom ^a   Jacobsson, Lars ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

particles; 211At; Autoradiography; Imaging; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MX 35 AT 211; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB AT 211; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAMERA; CHARGE COUPLED DEVICE; CONTROLLED STUDY; DIGITAL RADIOGRAPHY; DRUG DISTRIBUTION; EX VIVO STUDY; FEMALE; IMAGE ANALYSIS; IMAGE QUALITY; KIDNEY; KIDNEY CORTEX; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RADIOACTIVITY; RADIODIAGNOSTIC EQUIPMENT AND SUPPLIES; RADIOIMMUNOTHERAPY;

ALPHA PARTICLES; AUTORADIOGRAPHY; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; IMAGE ENHANCEMENT; SIGNAL PROCESSING, COMPUTER-ASSISTED; STATIC ELECTRICITY; TRANSDUCERS;

EID: 79851489246     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.077578     Document Type: Article

References (29)

1. Andersson H, Elgqvist J, Horvath G, et al. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clin Cancer Res. 2003;9:3914S-3921S.
2. Back T, Andersson H, Divgi CR, et al. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an α-emitter in vivo. J Nucl Med. 2005;46:2061-2067. (Pubitemid 46657454)
3. Elgqvist J, Andersson H, Back T, et al. α-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose. J Nucl Med. 2006;47:1342-1350. (Pubitemid 47544890)
4. Elgqvist J, Andersson H, Back T, et al. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with 211At-labeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907-1915. (Pubitemid 46196654)
5. Zalutsky MR. Targeted a-particle therapy of microscopic disease: providing a further rationale for clinical investigation. J Nucl Med. 2006;47:1238-1240. (Pubitemid 47544873)
6. Drecoll E, Gaertner FC, Miederer M, et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS ONE. 2009;4:e5715.
7. 211At-MX35 F(ab′)2: a phase I study. J Nucl Med. 2009;50:1153-1160.
8. 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008;49:30-38.
9. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990;31:75-83. (Pubitemid 20032527)
10. Humm JL, Macklis RM, Bump K, Cobb LM, Chin LM. Internal dosimetry using data derived from autoradiographs. J Nucl Med. 1993;34:1811-1817. (Pubitemid 23295398)
11. Humm JL, Roeske JC, Fisher DR, Chen GT. Microdosimetric concepts in radio-immunotherapy. Med Phys. 1993;20:535-541.
12. Akabani G, Kennel SJ, Zalutsky MR. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images. J Nucl Med. 2003;44:792-805. (Pubitemid 39655215)
13. Wood RW. The scintillations of radium. Science. 1904;29:195-196.
14. Kolar ZI, Den Hollander W. 2003: a centennial of spinthariscope and scintillation counting. Appl Radiat Isot. 2004;61:261-266.
15. Lindegren S, Andersson H, Back T, Jacobsson L, Karlsson B, Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate. Nucl Med Biol. 2001;28:33-39. (Pubitemid 32155963)
16. Lindegren S, Back T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157-160. (Pubitemid 32241030)
17. Welshinger M, Yin BW, Lloyd KO. Initial immunochemical characterization of MX35 ovarian cancer antigen. Gynecol Oncol. 1997;67:188-192. (Pubitemid 27500418)
18. Yin BW, Kiyamova R, Chua R, et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer Immun. 2008;8:3-11.
19. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29:57-61.
20. 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med. 1999;40:1197-1203.
21. 211At]astatine. Bioconjug Chem. 2009;20:1983-1991.
22. 211At. Nucl Med Biol. 2003;30:351-359.
23. d'Argy R, Sundwall A. Quantitative whole-body radioluminography: future strategy for balance and tissue distribution studies. Regul Toxicol Pharmacol. 2000;31:S57-S62.
24. Ullberg S. Studies on the distribution and fate of S35-labelled benzylpenicillin in the body. Acta Radiol Suppl. 1954;118:1-110.
25. Bayley ST. Autoradiography of single cells. Nature. 1947;160:193-194.
26. Branson H, Hansborough LA. The quantitative theory of autoradiography illustrated through experiments with P32 in the chick embryo. Science. 1948;108:327-328.
27. 211At: analyses of tumour retention, microdistribution and growth delay. Br J Cancer. 1998;77:1115-1122.
28. Neti PV, Howell RW. Log normal distribution of cellular uptake of radioactivity: implications for biologic responses to radiopharmaceuticals. J Nucl Med. 2006;47:1049-1058. (Pubitemid 46939959)
29. Neti PV, Howell RW. Lognormal distribution of cellular uptake of radioactivity: statistical analysis of a-particle track autoradiography. J Nucl Med. 2008;49:1009-1016. (Pubitemid 351793443)